Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 32,900 shares, a growth of 51.6% from the November 15th total of 21,700 shares. Currently, 1.0% of the company’s stock are sold short. Based on an average trading volume of 25,200 shares, the short-interest ratio is currently 1.3 days.

Artelo Biosciences Trading Up 0.9 %

Artelo Biosciences stock traded up $0.01 during mid-day trading on Friday, hitting $1.11. The company had a trading volume of 19,789 shares, compared to its average volume of 35,183. The company has a market capitalization of $3.58 million, a price-to-earnings ratio of -0.39 and a beta of 1.29. The company’s fifty day moving average is $1.14 and its 200-day moving average is $1.23. Artelo Biosciences has a 12-month low of $1.00 and a 12-month high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.06. As a group, sell-side analysts expect that Artelo Biosciences will post -2.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ARTL has been the subject of several research analyst reports. EF Hutton Acquisition Co. I raised shares of Artelo Biosciences to a “strong-buy” rating in a research report on Tuesday, October 1st. D. Boral Capital reissued a “buy” rating and set a $6.00 target price on shares of Artelo Biosciences in a report on Monday, December 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Artelo Biosciences in a report on Monday, December 9th.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.